doi:10.48130/targetome-0026-0029

[1]

Hassoun PM. 2021. Pulmonary arterial hypertension. New England Journal of Medicine 385:2361−2376

doi: 10.1056/NEJMra2000348

[2]

Yu LL, Jiang DS, Wang X, Fang ZM, Chen WH, et al. 2025. Global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021 and projections to 2040: a systematic analysis of incidence, mortality, and disability-adjusted life years. Current Medical Science 45:1068−1078

doi: 10.1007/s11596-025-00108-1

[3]

Emmons-Bell S, Johnson C, Boon-Dooley A, Corris PA, Leary PJ, et al. 2022. Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the Global Burden of Disease 2020 Study. Pulmonary Circulation 12:e12020

doi: 10.1002/pul2.12020

[4]

Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, et al. 2022. Mortality in pulmonary arterial hypertension in the modern era: early insights from the Pulmonary Hypertension Association Registry. Journal of the American Heart Association 11:e024969

doi: 10.1161/JAHA.121.024969

[5]

Hartley A, Singh H, Jani C, Salciccioli JD, Shalhoub J, et al. 2024. Mortality from pulmonary hypertension in Europe 2001−2019. BMC Pulmonary Medicine 24:415

doi: 10.1186/s12890-024-03235-y

[6]

Boucetta H, Zhang L, Sosnik A, He W. 2024. Pulmonary arterial hypertension nanotherapeutics: new pharmacological targets and drug delivery strategies. Journal of Controlled Release 365:236−258

doi: 10.1016/j.jconrel.2023.11.012

[7]

Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, et al. 2010. Smad-dependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circulation Research 107:252−262

doi: 10.1161/CIRCRESAHA.109.209940

[8]

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, et al. 2023. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal 61:2200879

doi: 10.1183/13993003.00879-2022

[9]

Zhang ZQ, Zhu SK, Wang M, Wang XA, Tong XH, et al. 2022. New progress in diagnosis and treatment of pulmonary arterial hypertension. Journal of Cardiothoracic Surgery 17:216

doi: 10.1186/s13019-022-01947-y

[10]

Ewert R, Habedank D, Halank M, Stubbe B, Opitz CF. 2022. Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension. Expert Review of Respiratory Medicine 16:57−66

doi: 10.1080/17476348.2022.2011220

[11]

Lindegaard Pedersen M, Krüger M, Grimm D, Infanger M, Wehland M. 2020. The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension. Basic & Clinical Pharmacology & Toxicology 126:32−42

doi: 10.1111/bcpt.13305

[12]

Gomberg-Maitland M, Olschewski H. 2008. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal 31:891−901

doi: 10.1183/09031936.00097107

[13]

Waxman AB, McElderry HT, Gomberg-Maitland M, Burke MC, Ross EL, et al. 2017. Totally implantable IV treprostinil therapy in pulmonary hypertension assessment of the implantation procedure. Chest 152:1128−1134

doi: 10.1016/j.chest.2017.04.188

[14]

Chakinala MM, Feldman JP, Rischard F, Mathier M, Broderick M, et al. 2017. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation 36:193−201

doi: 10.1016/j.healun.2016.06.019

[15]

Ewert R, Richter MJ, Steringer-Mascherbauer R, Grünig E, Lange TJ, et al. 2017. Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clinical Research in Cardiology 106:776−783

doi: 10.1007/s00392-017-1114-1

[16]

Desole S, Richter MJ, Heine A, Ewert R. 2019. Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension. Pulmonary Circulation 9:1−5

doi: 10.1177/2045894018788846

[17]

Shapiro S, Bourge RC, Pozella P, Harris DF, Borg EH, et al. 2020. Implantable system for treprostinil: a real-world patient experience study. Pulmonary Circulation 10:1−10

doi: 10.1177/2045894020907881

[18]

Lai Y, Xie B, Zhang W, He W. 2025. Pure drug nanomedicines - where we are? Chinese Journal of Natural Medicines 23:385−409

doi: 10.1016/s1875-5364(25)60851-x

[19]

Zou J, He X, Li Z, Song B, Xing X, et al. 2025. Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development. Targetome 1:e005

doi: 10.48130/targetome-0025-0003

[20]

Zoulikha M, Chen Z, Wu J, He W. 2025. Approved delivery strategies for biopharmaceuticals. Chinese Chemical Letters 36:110225

doi: 10.1016/j.cclet.2024.110225

[21]

Huang X, Brazel CS. 2001. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. Journal of Controlled Release 73:121−136

doi: 10.1016/S0168-3659(01)00248-6

[22]

Cheng Y, Zhang H, Wei H, Yu CY. 2024. Injectable hydrogels as emerging drug-delivery platforms for tumor therapy. Biomaterials Science 12:1151−1170

doi: 10.1039/D3BM01840G

[23]

Bonetti L, De Nardo L, Farè S. 2021. Thermo-responsive methylcellulose hydrogels: from design to applications as smart biomaterials. Tissue Engineering Part B: Reviews 27:486−513

doi: 10.1089/ten.teb.2020.0202

[24]

Pandya AK, Vora LK, Umeyor C, Surve D, Patel A, et al. 2023. Polymeric in situ forming depots for long-acting drug delivery systems. Advanced Drug Delivery Reviews 200:115003

doi: 10.1016/j.addr.2023.115003

[25]

Li J, Mooney DJ. 2016. Designing hydrogels for controlled drug delivery. Nature Reviews Materials 1:16071

doi: 10.1038/natrevmats.2016.71

[26]

Jiang Y, Krishnan N, Heo J, Fang RH, Zhang L. 2020. Nanoparticle-hydrogel superstructures for biomedical applications. Journal of Controlled Release 324:505−521

doi: 10.1016/j.jconrel.2020.05.041

[27]

Choi W, Kohane DS. 2024. Hybrid nanoparticle-hydrogel systems for drug delivery depots and other biomedical applications. ACS Nano 18:22780−22792

doi: 10.1021/acsnano.4c06888

[28]

Li Y, Chen Y, Xue Y, Jin J, Xu Y, et al. 2024. Injectable hydrogel delivery system with high drug loading for prolonging local anesthesia. Advanced Science 11:2309482

doi: 10.1002/advs.202309482

[29]

Lin C, Teng C, Li B, He W. 2025. Anti-inflammatory drug-assisted microRNA gene therapy for effectively improving pulmonary hemodynamics. Chinese Chemical Letters 36:110450

doi: 10.1016/j.cclet.2024.110450

[30]

Chai Z, Ran D, Lu L, Zhan C, Ruan H, et al. 2019. Ligand-modified cell membrane enables the targeted delivery of drug nanocrystals to glioma. ACS Nano 13:5591−5601

doi: 10.1021/acsnano.9b00661

[31]

Wu S, Lu L, Zhou J, Ran D, Wang S, et al. 2022. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals. Journal of Controlled Release 345:685−695

doi: 10.1016/j.jconrel.2022.03.047

[32]

Das B, Basu A, Maji S, Dutta K, Dewan M, et al. 2020. Nanotailored hyaluronic acid modified methylcellulose as an injectable scaffold with enhanced physico-rheological and biological aspects. Carbohydrate Polymers 237:116146

doi: 10.1016/j.carbpol.2020.116146

[33]

Wang Y, Li L, Ma Y, Tang Y, Zhao Y, et al. 2020. Multifunctional supramolecular hydrogel for prevention of epidural adhesion after laminectomy. ACS Nano 14:8202−8219

doi: 10.1021/acsnano.0c01658

[34]

Zhang H, Yang Z, Wu D, Hao B, Liu Y, et al. 2023. The effect of polymer blends on the in vitro release/degradation and pharmacokinetics of moxidectin-loaded PLGA microspheres. International Journal of Molecular Sciences 24:14729

doi: 10.3390/ijms241914729

[35]

Hong J, Arneson D, Umar S, Ruffenach G, Cunningham CM, et al. 2021. Single-cell study of two rat models of pulmonary arterial hypertension reveals connections to human pathobiology and drug repositioning. American Journal of Respiratory and Critical Care Medicine 203:1006−1022

doi: 10.1164/rccm.202006-2169OC

[36]

Deng R, Zhao R, Zhang Z, Chen Y, Yang M, et al. 2024. Chondrocyte membrane-coated nanoparticles promote drug retention and halt cartilage damage in rat and canine osteoarthritis. Science Translational Medicine 16:eadh9751

doi: 10.1126/scitranslmed.adh9751

[37]

Song Y, Cong Y, Wang B, Zhang N. 2020. Applications of Fourier transform infrared spectroscopy to pharmaceutical preparations. Expert Opinion on Drug Delivery 17:551−571

doi: 10.1080/17425247.2020.1737671

[38]

Ma X, Xu T, Chen W, Qin H, Chi B, et al. 2018. Injectable hydrogels based on the hyaluronic acid and poly (γ-glutamic acid) for controlled protein delivery. Carbohydrate Polymers 179:100−109

doi: 10.1016/j.carbpol.2017.09.071

[39]

Dhanka M, Pawar V, Chauhan DS, Jain NK, Prabhuraj RS, et al. 2021. Synthesis and characterization of an injectable microparticles integrated hydrogel composite biomaterial: in-vivo biocompatibility and inflammatory arthritis treatment. Colloids and Surfaces B: Biointerfaces 201:111597

doi: 10.1016/j.colsurfb.2021.111597

[40]

Li Z, Xu W, Yang J, Wang J, Wang J, et al. 2022. A tumor microenvironments-adapted polypeptide hydrogel/nanogel composite boosts antitumor molecularly targeted inhibition and immunoactivation. Advanced Materials 34:e2200449

doi: 10.1002/adma.202200449

[41]

Colombo E, Polito L, Biocotino M, Marzullo P, Hyeraci M, et al. 2020. New class of betulinic acid-based nanoassemblies of cabazitaxel, podophyllotoxin, and thiocolchicine. ACS Medicinal Chemistry Letters 11:895−898

doi: 10.1021/acsmedchemlett.9b00668

[42]

Trubitsyn G, Nguyen VN, Di Tommaso C, Borchard G, Gurny R, et al. 2019. Impact of covalently Nile Red and covalently Rhodamine labeled fluorescent polymer micelles for the improved imaging of the respective drug delivery system. European Journal of Pharmaceutics and Biopharmaceutics 142:480−487

doi: 10.1016/j.ejpb.2019.07.020

[43]

Jordan A, Whymark KD, Sydenham J, Sneddon HF. 2021. A solvent-reagent selection guide for Steglich-type esterification of carboxylic acids. Green Chemistry 23:6405−6413

doi: 10.1039/D1GC02251B

[44]

Du S, Wang H, Geng F, Zhang Z, Liu C, et al. 2026. Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma. Acta Pharmaceutica Sinica B 16:1140−1154

doi: 10.1016/j.apsb.2025.12.026

[45]

Zhang Y, Huo M, Zhou J, Xie S. 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Computer Methods and Programs in Biomedicine 99:306−314

doi: 10.1016/j.cmpb.2010.01.007

[46]

Wang AP, Yang F, Tian Y, Su JH, Gu Q, et al. 2021. Pulmonary artery smooth muscle cell senescence promotes the proliferation of PASMCs by paracrine IL-6 in hypoxia-induced pulmonary hypertension. Frontiers in Physiology 12:656139

doi: 10.3389/fphys.2021.656139

[47]

Dai J, Chen H, Fang J, Wu S, Jia Z. 2025. Vascular remodeling: the multicellular mechanisms of pulmonary hypertension. International Journal of Molecular Sciences 26:4265

doi: 10.3390/ijms26094265

[48]

Judina A, Niglas M, Leonov V, Kirkby NS, Diakonov I, et al. 2023. Pulmonary hypertension-associated right ventricular cardiomyocyte remodelling reduces treprostinil function. Cells 12:2764

doi: 10.3390/cells12232764

[49]

Zoulikha M, Zou J, Yang P, Wu J, Wu W, et al. 2025. Cocrystal pleomorphism-inspired drug nanoassembly for pulmonary-endothelium targeting and pulmonary hypertension treatment. Acta Pharmaceutica Sinica B 15:557−570

doi: 10.1016/j.apsb.2024.11.008

[50]

Chi PL, Cheng CC, Wang MT, Liao JB, Kuo SH, et al. 2024. Induced pluripotent stem cell-derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2. Cardiovascular Research 120:203−214

doi: 10.1093/cvr/cvad185

[51]

Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, et al. 2012. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. European Respiratory Journal 40:618−629

doi: 10.1183/09031936.00084211

[52]

Ho MJ, Jeong MY, Jeong HT, Kim MS, Park HJ, et al. 2022. Effect of particle size on in vivo performances of long-acting injectable drug suspension. Journal of Controlled Release 341:533−547

doi: 10.1016/j.jconrel.2021.12.011

[53]

Xu Z, Liu T, Jiang Y, Chen Z, Shi X, et al. 2022. Microcrystals of ketal-linked paliperidone prodrugs for long-acting antipsychotics. Molecular Pharmaceutics 19:3846−3857

doi: 10.1021/acs.molpharmaceut.2c00348

[54]

Kim MH, Kim BS, Park H, Lee J, Park WH. 2018. Injectable methylcellulose hydrogel containing calcium phosphate nanoparticles for bone regeneration. International Journal of Biological Macromolecules 109:57−64

doi: 10.1016/j.ijbiomac.2017.12.068

[55]

Chen H, Xu J, Sun J, Jiang Y, Zheng W, et al. 2024. Recent advances on thermosensitive hydrogels-mediated precision therapy. Asian Journal of Pharmaceutical Sciences 19:100911

doi: 10.1016/j.ajps.2024.100911

[56]

Wang L, Xu J, Xue P, Liu J, Luo L, et al. 2021. Thermo-sensitive hydrogel with mussel-inspired adhesion enhanced the non-fibrotic repair effect of EGF on colonic mucosa barrier of TNBS-induced ulcerative colitis rats through macrophage polarizing. Chemical Engineering Journal 416:129221

doi: 10.1016/j.cej.2021.129221

[57]

Bonetti L, Borsacchi S, Soriente A, Boccali A, Calucci L, et al. 2024. Injectable in situ gelling methylcellulose-based hydrogels for bone tissue regeneration. Journal of Materials Chemistry B 12:4427−4440

doi: 10.1039/D3TB02414H

[58]

Chapman RW, Corboz MR, Malinin VS, Plaunt AJ, Konicek DM, et al. 2020. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulmonary Pharmacology & Therapeutics 65:102002

doi: 10.1016/j.pupt.2021.102002

[59]

Abdelkader H, Fathalla Z, Seyfoddin A, Farahani M, Thrimawithana T, et al. 2021. Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: inserts, patches, wafers, and implants. Advanced Drug Delivery Reviews 177:113957

doi: 10.1016/j.addr.2021.113957

[60]

Wan B, Bao Q, Burgess D. 2023. Long-acting PLGA microspheres: advances in excipient and product analysis toward improved product understanding. Advanced Drug Delivery Reviews 198:114857

doi: 10.1016/j.addr.2023.114857

[61]

Herrick AL, Murray A, Dinsdale G, Manning J, Chukwu C, et al. 2025. An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in SSc-related RP. Rheumatology 64:5498−5503

doi: 10.1093/rheumatology/keaf291

[62]

Chenel M, Fouliard S, Hansson E, Brendel K, Jacobs M, et al. 2025. The evolving role of in vitro-in vivo correlation in model-informed drug development: a multi-stakeholder perspective. CPT: Pharmacometrics & Systems Pharmacology 14:1904−1907

doi: 10.1002/psp4.70137

[63]

Yanev P, van Tilborg GAF, Boere KWM, Stowe AM, van der Toorn A, et al. 2023. Thermosensitive biodegradable hydrogels for local and controlled cerebral delivery of proteins: MRI-based monitoring of in vitro and in vivo protein release. ACS Biomaterials Science & Engineering 9:760−772

doi: 10.1021/acsbiomaterials.2c01224

[64]

Zhao J, Jiang GQ, Sun JL, Zhang K, Ding FX. 2010. In vitro and in vivo morphology and degradation of chitosan based thermosensitive hydrogel as drug release matrix. Journal of Chemical Engineering of Chinese Universities 24:456−461

doi: 10.3969/j.issn.1003-9015.2010.03.016

[65]

Chen W, Shi K, Liu J, Yang P, Han R, et al. 2023. Sustained co-delivery of 5-fluorouracil and cis-platinum via biodegradable thermo-sensitive hydrogel for intraoperative synergistic combination chemotherapy of gastric cancer. Bioactive Materials 23:1−15

doi: 10.2139/ssrn.4182840

[66]

Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, et al. 2019. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. The Lancet Respiratory Medicine 7:239−248

doi: 10.1016/S2213-2600(18)30367-9

[67]

Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, et al. 2005. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 172:1586−1589

doi: 10.1016/s8756-3452(08)70403-1

[68]

Singh E, Bisserier M. 2025. Experimental animal models and patient-derived platforms to bridge preclinical discovery and translational therapeutics in pulmonary arterial hypertension. Journal of Translational Medicine 23:665

doi: 10.1186/s12967-025-06709-7

[69]

Hojda SE, Chis IC, Mîrza TV, Clichici S. 2024. Monocrotaline-induced pulmonary arterial hypertension: the benefic effects of magnesium sulfate, rosuvastatin and sildenafil. Medicine and Pharmacy Reports 97:528−539

doi: 10.15386/mpr-2804

[70]

Hill NS, Gillespie MN, McMurtry IF. 2017. Fifty years of monocrotaline-induced pulmonary hypertension: what has it meant to the field? Chest 152:1106−1108

doi: 10.1016/j.chest.2017.10.007

[71]

Rubin LJ. 2016. Are animal models in pulmonary hypertension relevant to the clinical disease? Journal of the American College of Cardiology 67:2047−2049

doi: 10.1016/j.jacc.2016.03.002

[72]

Corboz MR, Nguyen TL, Stautberg A, Cipolla D, Perkins WR, et al. 2024. Current overview of the biology and pharmacology in sugen/hypoxia-induced pulmonary hypertension in rats. Journal of Aerosol Medicine and Pulmonary Drug Delivery 37:241−283

doi: 10.1089/jamp.2024.0016

[73]

Jin Q, Chen D, Zhang X, Zhang F, Zhong D, et al. 2023. Medical management of pulmonary arterial hypertension: current approaches and investigational drugs. Pharmaceutics 15:1579

doi: 10.3390/pharmaceutics15061579

[74]

Wang JJ, Jin S, Zhang H, Xu Y, Hu W, et al. 2024. Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs. Science Advances 10:eadk5184

doi: 10.1126/sciadv.adk5184